Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZLAB
STRONG SELLZai Lab Limited · Healthcare · China · $2.1B
COMPANY DESCRIPTION
Zai Lab Limited is a commercial-stage biopharmaceutical company focused on bringing transformative medicines to patients in China and globally. The company's competitive moat is its highly successful in-licensing model, which partners with global biopharma leaders to commercialize late-stage assets in the Greater China market. It is a leading, vertically integrated biotechnology company with a robust pipeline in oncology, autoimmune, and infectious diseases.
Insufficient price history for this range.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZLAB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZLAB | Zai Lab Limited(you) | $2.1B | 9 | STRONG SELL |
| 9606.HK | Duality Biotherapeutics, Inc. | $2.1B | 7 | STRONG SELL |
| 688166.SS | BrightGene Bio-Medical Technology Co., Ltd. | $2.3B | 9 | STRONG SELL |
| 7666.HK | METIS TECHBIO-P | $2.2B | 12 | STRONG SELL |
| 688520.SS | Sinocelltech Group Limited | $2.3B | 6 | STRONG SELL |
| 6872.HK | TENNOR THERAP-B | $1.8B | 6 | STRONG SELL |
| 688382.SS | InventisBio Co., Limited | $1.4B | 7 | STRONG SELL |
| 688062.SS | Mabwell (Shanghai) Bioscience Co., Ltd. | $1.8B | 3 | STRONG SELL |
| 300204.SZ | Staidson (Beijing) BioPharmaceuticals Co., Ltd. | $1.4B | 11 | STRONG SELL |
| 1877.HK | Shanghai Junshi Biosciences Co., Ltd. | $2.1B | 18 | STRONG SELL |
Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.2%